September 29, 2021

Fail Early, Fail Fast


Kevin Hampton, former SVP of Biopharma

“Biotech executives are addressing a multitude of strategic priorities daily. However, prioritizing indications and executing the right portfolio program are becoming more challenging. If you are going to fail eventually, it’s better, and much less costly, to fail earlier, so fail fast.”